Comparison

AMGEN INC (AMGN) vs PFIZER INC (PFE)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

AMGN

AMGEN INC

Drug Manufacturers—General

Revenue, FY25: $36.75B
Net income: $7.71B
Operating cash flow: $9.96B
Free cash flow: $8.1B
Net margin: 20.98%
Operating margin: 24.71%
Gross margin: 67.25%

PFE

PFIZER INC

Drug Manufacturers—General

Revenue, FY25: $62.58B
Net income: $7.77B
Operating cash flow: $11.7B
Free cash flow: $9.08B
Net margin: 12.42%
Operating margin: -
Gross margin: 74.33%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	AMGN	PFE
Revenue growth, latest filed year	+9.95%	−1.65%
Piotroski F-score	7 of 9	5 of 9
P/E against its own history	about normal	94.57% above

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

AMGN

FDA approval
Reimbursement
Cybersecurity
Litigation
China
Tax

And 20 more.

PFE

No 10-K read yet.

Tracked managers holding both

Joel Greenblatt Gotham Asset Management 0.04% · 0.05%
Dodge & Cox Dodge & Cox 0.00% · 0.00%

Updated Aug 5, 2026 · the newer of the two companies' filings